Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States.

Conclusion: The current HPV vaccination program is predicted to be cost saving. Extending vaccination to older ages is predicted to produce small additional health benefits and result in substantially higher incremental cost-effectiveness ratios than the current recommendation.
Primary Funding Source: Centers for Disease Control and Prevention.
PMID: 31816629 [PubMed - as supplied by publisher]

Source: Annals of Internal Medicine - December 9, 2019 Category: Internal Medicine Authors: Laprise JF, Chesson HW, Markowitz LE, Drolet M, Martin D, Bénard É, Brisson M Tags: Ann Intern Med Source Type: research